When Treatments & Trials for Rare Disorders Exclude Malaysia
Catherine Jayasuriya, Founder & Executive Director, Coalition Duchenne | Nadiah Hanim Abdul Latif, President, Malaysia Rare Disorders Society
23-Jul-25 16:00

Embed Podcast
You can share this podcast by copying this HTML to your clipboard and pasting into your blog or web page.
Close
About 95% of rare disorders don’t have a treatment for it, and even in cases where treatment is available or a clinical trial is being conducted, not everyone across the world has equal access to it. That’s what’s happening now in the context of Duchenne Muscular Dystrophy. Here to help us dive into this and why equitable access to treatments matter, we speak to Catherine Jayasuriya, Founder & Executive Director, Coalition Duchenne, and Nadiah Hanim Abdul Latif, President, Malaysia Rare Disorders Society.
Image Credit: Catherine Jayasuriya
Produced by: Lim Sue Ann
Presented by: Lim Sue Ann
This and more than 60,000 other podcasts in your hand. Download the all new BFM mobile app.
Categories: managing disease, medical advances
Tags: the bigger picture, health & living, rare disease, rare disorders, duchenne muscular dystrophy, health equity,